![conference banner](/images/conference-banner.jpeg)
Abstract
Chordoma is a rare type of tumor of the skeletal system that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordoma is a slowly growing primary tumor that arise from an intra-osseous remnant of notochordal cells. These neoplasms typically occur in the axial skeleton; the most common location is the sacrococcygeal region followed by skull base and spine. Chordomas typically occur in adults between ages 50 and 70. About five percent of them are diagnosed in children. Males are affected about twice as often as females.
Histopathologically, chordomas are divided into conventional (the most common) type, chondroid, and dedifferentiated types. They are mainly locally aggressive with gradual involvement of bone and soft tissues. However, metastases have been reported mainly at late stages. Aggressive initial therapy, based on maximal possible resection followed by postoperative irradiation, improves overall outcome. Up to 40 percent of patients recur after treatment showing a poor prognosis but both radiation and surgery can be used as salvage therapy. Radiation therapy is used in order to treat patients with advanced, residual, inoperable lesions or with local recurrence. Particle therapy (protons and ions) has been reported as a very active form of irradiation for its peculiar physical properties. Chordomas are reported as tumors non sensitive to chemotherapy; molecularly targeted therapies are increasingly used in recent years with promising results but deserve further investigation.Keywords: Chordoma, particle therapy, radiotherapy, sacrum, skull base, spine
Current Drug Therapy
Title:Current Concepts on the Management of Chordoma
Volume: 7 Issue: 4
Author(s): Maurizio Amichetti, Dante Amelio, Barbara Rombi, Sabina Vennarini and Marco Cianchetti
Affiliation:
Keywords: Chordoma, particle therapy, radiotherapy, sacrum, skull base, spine
Abstract: Chordoma is a rare type of tumor of the skeletal system that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordoma is a slowly growing primary tumor that arise from an intra-osseous remnant of notochordal cells. These neoplasms typically occur in the axial skeleton; the most common location is the sacrococcygeal region followed by skull base and spine. Chordomas typically occur in adults between ages 50 and 70. About five percent of them are diagnosed in children. Males are affected about twice as often as females.
Histopathologically, chordomas are divided into conventional (the most common) type, chondroid, and dedifferentiated types. They are mainly locally aggressive with gradual involvement of bone and soft tissues. However, metastases have been reported mainly at late stages. Aggressive initial therapy, based on maximal possible resection followed by postoperative irradiation, improves overall outcome. Up to 40 percent of patients recur after treatment showing a poor prognosis but both radiation and surgery can be used as salvage therapy. Radiation therapy is used in order to treat patients with advanced, residual, inoperable lesions or with local recurrence. Particle therapy (protons and ions) has been reported as a very active form of irradiation for its peculiar physical properties. Chordomas are reported as tumors non sensitive to chemotherapy; molecularly targeted therapies are increasingly used in recent years with promising results but deserve further investigation.Export Options
About this article
Cite this article as:
Amichetti Maurizio, Amelio Dante, Rombi Barbara, Vennarini Sabina and Cianchetti Marco, Current Concepts on the Management of Chordoma, Current Drug Therapy 2012; 7 (4) . https://dx.doi.org/10.2174/157488512804999127
DOI https://dx.doi.org/10.2174/157488512804999127 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Image Guided Biopsy of Musculoskeletal Lesions with Low Diagnostic Yield
Current Medical Imaging Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Role of Non-coding RNA in the Pathogenesis of Intestinal Ischemia- Reperfusion Injury
Current Medicinal Chemistry The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Molecular Links Between Diabetes and Osteoarthritis: The Role of Physical Activity
Current Diabetes Reviews Cancer Metastasis as Disrupted Developmental Phenotype
Current Genomics Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry MicroRNA-96 is Downregulated in Sepsis Neonates and Attenuates LPSInduced Inflammatory Response by Inhibiting IL-16 in Monocytes
Combinatorial Chemistry & High Throughput Screening NMR-based Drug Development and Improvement Against Malignant Melanoma – Implications for the MIA Protein Family
Current Medicinal Chemistry Synthesis and Biological Evaluation of Some Hydrazone Derivatives as Anti-inflammatory Agents
Letters in Drug Design & Discovery Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets LncRNAs as Therapeutic Targets for Autophagy-involved Cardiovascular Diseases: A Review of Molecular Mechanism and T herapy Strategy
Current Medicinal Chemistry The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry